Elevated FGF23 serum levels associate with endothelial dysfunction and small vessel disease, stroke, and brain infarction in patients with CKD stage 3–4 (40) and in the general population (58, 61, 88), respectively. This evidence concerns the gene FGF23 and chronic kidney disease.